Researchers sought to determine whether combining enasidenib with venetoclax would be effective in patients with IDH2-mutated ...

This transcript has been edited for clarity. Gail J. Roboz, MD: Hi, everyone. My name is Dr Gail Roboz. I'm a professor of medicine and director of the leukemia program at Weill Cornell Medicine and ...

Leukemia researchers led by Dr. John Dick have traced the origins of relapse in acute myeloid leukemia (AML) to rare therapy-resistant leukemia stem cells that are already present at diagnosis and ...

– Primary endpoint met with CR/CRh rate of 23% in pivotal Ph 2 cohort of R/R mNPM1 AML patients (p-value = 0.0014) – – 47% (30/64) ORR in a heavily pre-treated population, including 75% with prior ...

AlloHeme test accurately predicts relapse post-allo-HSCT in AML and MDS, with a median lead time of 36 days. The ACROBAT study involved 287 patients, showing significant predictive value of increased ...

The study reported 10-year survival rates of 81.3% for ALL and 76.2% for AML post-HCT. Relapse and cGVHD were the primary causes of late mortality, with relapse contributing to 33.9% of ALL and 44.9% ...

Relapses in a common form of leukemia may be preventable following new research that has identified how the cancer develops resistance to first line treatments. Relapses in a common form of leukemia ...

In a groundbreaking development, First Ascent Biomedical unveils a compelling narrative of resilience and innovation through ...

AVEO Oncology, an LG Chem company, (AVEO) announced today that the first patient has been successfully dosed in a Phase 1b/2 clinical trial evaluating ficlatuzumab in combination with azacitidine and ...